Tenaya Therapeutics, Inc. TNYA
0.37 USD -0.02 (-5.94%)
At closeNov 10, 2026, 6:45 PM EST
0.37 0.00 0.00%
After hours · Nov 10, 6:45 PM ET
0.3706 Day range 0.4076
0.30 52-week range 1.56
- YTD
- -47.95%
- 1 year
- -74.08%
News
zacks.com Tenaya Therapeutics, Inc. (TNYA) Reports Q3 Loss, Beats Revenue Estimates Tenaya Therapeutics, Inc. (TNYA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.12 per share a year ago.
benzinga.com Tenaya Therapeutics Q3 EPS $(0.08) Beats $(0.10) Estimate, Sales $1.697M Beat $800.000K Estimate Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 percent. This is a 33.33 percent increase over losses of…
globenewswire.com Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy TN-201 and TN-401 Program…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers MaxCyte (NASDAQ:MXCT) shares rose 34.5% to $1.3 during Wednesday's regular session. The company's market cap stands at $102.6 million. Liquidia (NASDAQ:LQDA) stock moved upwards by 26.29% to…
benzinga.com FDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory…- benzinga.com Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.05) by 300 percent. This is a 42.86 percent decrease over losses of…
benzinga.com Tenaya Therapeutics Appoints Eric Hyllengren CFO, Effective July 13 Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
benzinga.com Tenaya Therapeutics Reports New Interim Safety And Efficacy Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201 All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCMBenefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom…
benzinga.com Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3 Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
benzinga.com Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements Tenaya reported early RIDGE-1 data showing reduced arrhythmias and favorable safety for TN-401 in PKP2-related ARVC patients.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Tenaya Therapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $25.000M Beat $10.000M Estimate Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.06) by 50 percent. This is a 62.5 percent increase over losses of…
benzinga.com Tenaya Therapeutics Announces Acceptance Of Multiple Abstracts For Presentation At ASGCT Annual Meeting; To Feature New Clinical Data From Both Dose Cohorts Of RIDGE-1 Phase 1b/2 Trial Of TN-401 As Late-Breaking Oral Presentation Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCTAdditional Presentations at ASGCT Showcase Tenaya's Work with…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Tenaya Therapeutics Q4 EPS $(0.12) Beats $(0.13) Estimate Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 9.09 percent. This is a 57.14 percent increase over losses of…
benzinga.com Tenaya Therapeutics Presents Prelinical Data Of TN-301 At Muscular Dystrophy Association's Clinical & Scientific Conference 2026 Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
benzinga.com Tenaya Therapeutics Stock Jumps After New Alnylam Deal Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $1.13 billion in milestone payments.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com Tenaya Therapeutics Collaborates With Alnylam Pharmaceuticals To Discover Human Genetic Targets For Potential Development Of Disease-modifying Treatments For Cardiovascular Diseases Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
- benzinga.com Tenaya Therapeutics Issues Update On Clinical Development Programs And Outlines Strategic Priorities For 2026; Aims To Build On Positive 2025 Interim TN-201 Results In H1 2026 Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCMExpects to…
benzinga.com Tenaya Stock Plunges After $60 Million Equity Offering Heart disease-focused Tenaya Therapeutics falls on high volume after pricing a $60 million offering and releasing new TN-401 data, while the FDA clears the TN-201 trial hold.
benzinga.com S&P 500 Down 1%; Broadcom Earnings Top Views 
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com HC Wainwright & Co. Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $3 HC Wainwright & Co. analyst Joseph Pantginis maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $5 to $3.
benzinga.com Dow Rises Over 100 Points; Lululemon Posts Upbeat Q3 Earnings - benzinga.com Chardan Capital Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $8 Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $9 to $8.
- benzinga.com Tenaya Therapeutics Receives FDA Clearance To Resume MyPEAK‑1 Trial Of TN‑201 For MYBPC3‑Associated Hypertrophic Cardiomyopathy Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Tenaya Therapeutics Reports Interim RIDGE‑1 Trial Data For TN‑401 Gene Therapy In PKP2‑Mutated ARVC TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8Clinically Meaningful Reductions in Arrhythmia Burden…- benzinga.com Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.
- benzinga.com Tenaya Therapeutics Q3 EPS $(0.12) Beats $(0.15) Estimate Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 22.58 percent. This is a 60 percent increase over losses of…
- benzinga.com Reported Saturday, Tenaya Therapeutics Reports TN-201 Well Tolerated At 3E13 And 6E13 vg/kg With Managed Immunogenicity And No Dose-Limiting Toxicities In MyPEAK-1 MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular ResearchTN-201 Has Been Generally Well Tolerated at Both…
- benzinga.com FDA Places Clinical Hold On Tenaya Therapeutics' TN-201 Trial, Requests Protocol Amendment For Patient Monitoring And Immunosuppression Management The U.S. Food and Drug Administration ("FDA") has placed a clinical hold on MyPEAKTM-1,Tenaya Therapeutics, Inc.'s ("Tenaya") Phase 1b/2a clinical trial evaluating TN-201 in MYBPC3-associated…
- benzinga.com Tenaya Therapeutics To Give Two Late-breaking Oral Presentations At The American Heart Association 2025 Scientific Sessions Taking Place November 7-10, 2025 Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
benzinga.com Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.- benzinga.com HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $5 price target.
- benzinga.com Reported Sunday, Tenaya Highlights Urgent Need For Disease-Modifying Approaches In Pediatric MYBPC3-Associated HCM Based On MyClimb Interim Findings Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants93% of MyClimb Participants had the Nonobstructive Form of HCM for Which…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $5 price target.
- benzinga.com Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.
- benzinga.com Tenaya Therapeutics Q2 EPS $(0.14) Beats $(0.17) Estimate Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.17) by 17.65 percent. This is a 58.82 percent increase over losses of…
- benzinga.com Tenaya Therapeutics Completes Enrollment In MyPEAK-1 Trial For HCM And Initiates RIDGE-1 Trial For ARVC With DSMB Endorsements Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2…
- benzinga.com Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.
- benzinga.com Tenaya Therapeutics Q1 EPS $(0.24) Misses $(0.20) Estimate Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.20) by 20 percent. This is a 40 percent increase over losses of…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $5 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $5 price target.
- benzinga.com Tenaya Therapeutics Announces Late Breaker Presentation Of New Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201 At American College Of Cardiology Annual Meeting TN-201 Has Been Well Tolerated at 3E13 vg/kg DoseNew Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over TimeAll Cohort 1 Patients with…
- benzinga.com Tenaya Announces Preclinical Data For TN-201 Gene Therapy In Nature Communications: MYBPC3 Gene Replacement Shows Dose-Dependent MyBP-C Protein Increase, Reverses Left Ventricular Hypertrophy; TN-201 In Phase 1b/2 Trial For MYBPC3-Associated Hypertrophic Cardiomyopathy Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
- benzinga.com Tenaya Therapeutics Announced Presentation Of TN-201 Gene Therapy Data For MYBPC3-Associated Hypertrophic Cardiomyopathy At ACC 2025 In Chicago; Includes 1-Year Patient Assessments From MyPEAK-1 Phase 1b/2 Trial Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
- benzinga.com Canaccord Genuity Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $6 Canaccord Genuity analyst Whitney Ijem maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $18 to $6.
- benzinga.com Morgan Stanley Maintains Overweight on Tenaya Therapeutics, Lowers Price Target to $5 Morgan Stanley analyst Matthew Harrison maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Overweight and lowers the price target from $15 to $5.